Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Additional Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Next Previous
X
Search
Trial Profile

An Additional Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rovatirelin (Primary)
  • Indications Spinocerebellar ataxias
  • Focus Therapeutic Use
  • Sponsors Kissei Pharmaceutical

    • Most Recent Events

    • 19 Jul 2023 According to Kissei Pharmaceutical media release, the company decided to temporarily withdraw the application for marketing approval and discuss the possibility of conducting additional clinical trials with the Pharmaceuticals and Medical Devices Agency (PMDA), because the PMDA has recently expressed its opinion that the marketing approval based on the current clinical trial data would be difficult.
    • 22 Jan 2020 Results published in Kissei Pharmaceutical Media Release
    • 22 Jan 2020 According to Kissei Pharmaceutical media release, results from this trial been published in a medical journal, the online version of the Journal of Neurology, Neurosurgery, and Psychiatry

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top